[Comment] Can ropeginterferon SURPASS resistance in essential thrombocythaemia?

Essential thrombocythaemia is a clonal myeloproliferative neoplasm associated with a lifelong risk of arterial and venous thrombosis, haemorrhage, and disease progression to secondary myelofibrosis and acute leukaemia.1 Current management strategies are primarily guided by the estimated risk of thrombotic events, presence of extreme leukocytosis or thrombocytosis, and disease-related symptoms. Hydroxyurea remains the most widely used first-line cytoreductive therapy for essential thrombocythaemia.